Opko Health - Der nächste Blockbuster (Seite 272)
eröffnet am 10.12.13 19:42:20 von
neuester Beitrag 07.05.24 22:55:13 von
neuester Beitrag 07.05.24 22:55:13 von
Beiträge: 3.051
ID: 1.189.336
ID: 1.189.336
Aufrufe heute: 4
Gesamt: 261.285
Gesamt: 261.285
Aktive User: 0
ISIN: US68375N1037 · WKN: A0MUUJ · Symbol: XCY
1,2500
USD
-3,85 %
-0,0500 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
07.05.24 · globenewswire  |
03.05.24 · globenewswire |
05.03.24 · globenewswire |
27.02.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8450 | +146,00 | |
| 0,5700 | +55,23 | |
| 0,7200 | +47,03 | |
| 1,0000 | +33,33 | |
| 119,40 | +29,92 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,0000 | -12,50 | |
| 13,800 | -13,86 | |
| 4,1900 | -14,49 | |
| 0,9235 | -16,88 | |
| 5,2500 | -19,23 |
Beitrag zu dieser Diskussion schreiben
Feedback
OPKO Health's BioReference Laboratories Partners with Hospitals Nationwide to Provide Prioritized Testing to Inpatients with Suspected Coronavirus Disease 2019 (COVID-19)
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced that it will continue to prioritize COVID-19 testing for hospital inpatients and critically ill patients around the country.
"Our goal is to maintain the current 24 hour turnaround time for these patients," said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. "Nothing is more important than getting a timely result back to the medical personnel on the front lines making treatment decisions on a minute-to-minute basis."
"Multiple types of hospitals, for-profit, not-for-profit, large health systems, individual hospitals, academic medical centers, and community hospitals have all reached out to get their results in a timely fashion. We have now tested almost 200,000 patients and will continue to grow our capacity from 20,000 tests/day to 35,000 tests/day within the next week. While prioritizing hospital patients, at the same time we will continue to strive to keep our current turnaround time for non-hospital patients at 2-3 days from the time we receive the specimen," said Dr. Cohen.
https://finance.yahoo.com/news/opko-healths-bioreference-lab…
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced that it will continue to prioritize COVID-19 testing for hospital inpatients and critically ill patients around the country.
"Our goal is to maintain the current 24 hour turnaround time for these patients," said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. "Nothing is more important than getting a timely result back to the medical personnel on the front lines making treatment decisions on a minute-to-minute basis."
"Multiple types of hospitals, for-profit, not-for-profit, large health systems, individual hospitals, academic medical centers, and community hospitals have all reached out to get their results in a timely fashion. We have now tested almost 200,000 patients and will continue to grow our capacity from 20,000 tests/day to 35,000 tests/day within the next week. While prioritizing hospital patients, at the same time we will continue to strive to keep our current turnaround time for non-hospital patients at 2-3 days from the time we receive the specimen," said Dr. Cohen.
https://finance.yahoo.com/news/opko-healths-bioreference-lab…
Die Aktie heute deutlich im Plus.
Mal schauen warum ...
Mal schauen warum ...
Oder ihm geht's um was anderes.
Antwort auf Beitrag Nr.: 63.243.145 von Malecon am 05.04.20 14:42:33Wie viele braucht er noch um den Kurs in die Höhe zu treiben?? 😅
Der CEO hat wieder zugeschlagen.
Er bunkert immer mehr Aktien.
Notable Insider Buys In The Past Week
Opko Health Inc. (NASDAQ: OPK) CEO Phillip Frost, a frequent buyer, indirectly purchased almost 1.13 million shares of this biotech at $1.14 to $1.35 each. That totaled more than $1.59 million. Frost also added 300,000 shares the prior week.
https://finance.yahoo.com/news/notable-insider-buys-past-wee…
Er bunkert immer mehr Aktien.
Trading Spotlight
Na, bei über 6000 Mitarbeitern und vielen Produkten in der Pipeline ist da für OPKO genug Platz auf dem Markt, nicht umsonst erscheint das Unternehmen auf der Liste. Und dass es drei etwas stärkere gibt, war ja bekannt, das ist nun wirklich nichts neues.
Antwort auf Beitrag Nr.: 63.205.362 von Malecon am 01.04.20 19:00:57
Im Text steht leider direkt die Abstufung.
Der Kurs hat auch sofort drauf reagiert.
Zitat:
"Der US-Markt für klinische Labordiagnostik ist stark fragmentiert, und eine große Anzahl von Laboren bietet Dienstleistungen in verschiedenen Bundesstaaten des Landes
an. Einige Spieler haben jedoch den Vorsprung im Vergleich zu anderen Unternehmen. Quest Diagnostics, LabCorp und Sonic Healthcare sind die wichtigsten unabhängigen Laboratorien, die ihre Marktreichweite mit dem richtigen Fokus auf Konsolidierungsaktivitäten erweitert haben."
https://www.globenewswire.com/news-release/2020/04/01/200979…
kleine Ergänzung zum Bericht
Im Text steht leider direkt die Abstufung.
Der Kurs hat auch sofort drauf reagiert.
Zitat:
"Der US-Markt für klinische Labordiagnostik ist stark fragmentiert, und eine große Anzahl von Laboren bietet Dienstleistungen in verschiedenen Bundesstaaten des Landes
an. Einige Spieler haben jedoch den Vorsprung im Vergleich zu anderen Unternehmen. Quest Diagnostics, LabCorp und Sonic Healthcare sind die wichtigsten unabhängigen Laboratorien, die ihre Marktreichweite mit dem richtigen Fokus auf Konsolidierungsaktivitäten erweitert haben."
https://www.globenewswire.com/news-release/2020/04/01/200979…
The U.S. Clinical Laboratory Testing Market to 2022 - Key Players are LabCorp, OPKO Health, Sonic Healthcare, Quest Diagnostics, Alere, Abbott Labs, Charles River Labs, Healthscope, Genzyme and Qiagen
It is estimated that the market for clinical lab testing in the US is poised to witness healthy growth backed by factors such as the aging population, active private sector participation, and rising awareness level. With the emergence of new technologies, the market is likely to register further to an optimum CAGR in the future.
Currently, the market is dominated by clinical chemistry tests, followed by human & tumor genomics. The future, however, holds significant promise for human and tumor genomics testing. The future growth in this segment is driven by strong growth in personalized laboratory testing on tumor tissues and other key factors. The report, in this context, offers effective information and analysis on the market landscape for key tests type, with special emphasis on their future performance.
8. Key Players
8.1 Laboratory Corporation of America (LabCorp)
8.2 OPKO Health Inc.
8.3 Sonic Healthcare USA
8.4 Quest Diagnostics
8.5 Alere Inc.
8.6 Abbott Laboratories
8.7 Charles River Laboratories
8.8 Healthscope Ltd.
8.9 Genzyme (Subsidiary of Sanofi)
8.10 Qiagen
https://www.globenewswire.com/news-release/2020/04/01/200979…
It is estimated that the market for clinical lab testing in the US is poised to witness healthy growth backed by factors such as the aging population, active private sector participation, and rising awareness level. With the emergence of new technologies, the market is likely to register further to an optimum CAGR in the future.
Currently, the market is dominated by clinical chemistry tests, followed by human & tumor genomics. The future, however, holds significant promise for human and tumor genomics testing. The future growth in this segment is driven by strong growth in personalized laboratory testing on tumor tissues and other key factors. The report, in this context, offers effective information and analysis on the market landscape for key tests type, with special emphasis on their future performance.
8. Key Players
8.1 Laboratory Corporation of America (LabCorp)
8.2 OPKO Health Inc.
8.3 Sonic Healthcare USA
8.4 Quest Diagnostics
8.5 Alere Inc.
8.6 Abbott Laboratories
8.7 Charles River Laboratories
8.8 Healthscope Ltd.
8.9 Genzyme (Subsidiary of Sanofi)
8.10 Qiagen
https://www.globenewswire.com/news-release/2020/04/01/200979…
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Löschung auf Wunsch des Users, Posting versehentlich im falschen Thread erstellt
Antwort auf Beitrag Nr.: 63.182.916 von Malecon am 31.03.20 00:25:56🤔 wirklich positiv ist das aber nicht. Oder wie soll das gedeutet werden?
Opko hat viele Teststationen eingerichtet und es soll viel gestestet werden. Wann kommen Zahlen?
Opko hat viele Teststationen eingerichtet und es soll viel gestestet werden. Wann kommen Zahlen?
Durchsuchen
